2 results
Approved WMOCompleted
Study IM011-077 is a Phase 2 randomized, open-label, multicenter clinical study designed to assess the safety and tolerability, efficacy and biomarker response of deucravacitinib 6 mg BID (twice daily) in subjects with moderate to severe Ulcerative…
Approved WMORecruiting
Primary Objective: Primary objective of this trial will be to determine whether iNPWT reduces the number of patients with clinically relevant* SSOs after (potentially) contaminated ventral hernia repair <30 days after surgery. *A SSO is…